HIV-1/AIDS vaccine development: Are we in the darkness before the dawn?

Chinese Medical Journal

Volumn 121, Issue 10, 2008, Pages 939-945

  Qiu, Chao ^a,b   Xu, Jian Qing ^a,c  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Human immunodeficiency virus; Neutralization antibody; T cell immunity; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; DOUBLE STRANDED DNA; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; NEF PROTEIN; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POL PROTEIN; POLIOMYELITIS VACCINE; PROTEINASE; REV PROTEIN; SINGLE STRANDED RNA; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADENOVIRUS; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; INFLUENZA; NONHUMAN; REVERSE TRANSCRIPTION; SMALLPOX; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

EID: 51149112018     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200805020-00014     Document Type: Article

References (62)

1. Basavapathruni A, Anderson KS. Reverse transcription of the HIV-1 pandemic. Faseb J 2007; 21: 3795-3808.
2. Thomas M, Brady L. HIV integrase: a target for AIDS therapeutics. Trends Biotechnol 1997; 15: 167-172.
3. Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006; 8: 51-59.
4. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234: 1563-1566.
5. Wei Y, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
6. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77: 2165-2173.
7. Scott CF, Jr., Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci U S A 1990; 87: 8597-8601.
8. Ohno T, Terada M, Yoneda Y, Shea KW, Chambers RF, Stroka DM, et al. A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A 1991; 88: 10726-10729.
9. Burton DR, Pyati J, Koduri R, Sharp SJ, Thomton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-1027.
10. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018.
11. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 2001; 7: 1225-1231.
12. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
13. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996; 2: 1244-1247.
14. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-1265.
15. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
16. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency vims infection by CD8+ lymphocytes. Science 1999; 283: 857-860.
17. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-998.
18. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407: 386-390.
19. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3: 212-217.
20. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001; 193: 375-386.
21. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, Xu L, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312: 1530-1533.
22. Hu SL, Fultz PN, McClure HM, Eichberg JW, Thomas EK, Zarling J, et al. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 1987; 328: 721-723.
23. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987; 316: 673-676.
24. Maurer DM, Harrington B, Lane JM. Smallpox vaccine: contraindications, administration, and adverse reactions. Am Fam Physician 2003; 68: 889-896.
25. Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989, 246: 1293-1297.
26. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-1941.
27. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267: 1820-1825.
28. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5: 194-203.
29. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7: 19-23.
30. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14 Suppl3: s277-s289.
31. Cohen J. Public health. AIDS vaccine trial produces disappointment and confusion. Science 2003; 299: 1290-1291.
32. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37: 1385-1392.
33. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
34. She X, Siliciano RF. Preventing AIDS but not HIV-1 infection with a DNA vaccine. Science 2000; 290: 463-465.
35. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
36. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology application, and optimization. Annu Rev Immunol 2000; 18: 927-974.
37. Huang X, Xu J, Qiu C, Ren L, Liu L, Wan Y, et al. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine 2007; 25: 2620-2629.
38. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
39. Santra S, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Lord CI, et al. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J Immunol 2002; 168: 1847-1853.
40. Pamungkas J, De Rose R, Iskandriati D, Noviana R, Paramastri Y, Dale CJ, et al. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques. AIDS Res Hum Retroviruses 2005; 21; 292-300.
41. Tartaglia J, Perkus ME, Taylor J, Norton EY, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188: 217-232.
42. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205: 63-77.
43. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55: 355-372.
44. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007; 318: 1048-1049.
45. Ledford H. HIV vaccine may raise risk. Nature 2007; 450: 325.
46. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318: 28-29.
47. Schneider J, Gilbert SC, Hannan CM, Degano P, Prieur E, Sheu EG, et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999; 170: 29-38.
48. Ramshaw LA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21: 163-165.
49. Gaschen B, Taylor J, Yusim K, Foley P, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296: 2354-2360.
50. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol 2002; 76: 5435-5451.
51. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, et al. Consensus and ancestral state HIV vaccines. Science 2003; 299: 1515-1518; author reply 1515-1518.
52. Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M, et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007; 15: 411-421.
53. Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, Heath L, et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 2007; 81: 8507-8514.
54. Kong WP, Huang Y, Yang ZY, Chakrabarti BK, Moodie Z, Nabel GJ. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003; 77: 12764-12772.
55. Chakrabarti BK, Ling X, Yang ZY, Montefiori DC, Panet A, Kong WP, et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005; 23: 3434-3445.
56. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005; 79: 2956-2963.
57. Wu L, Kong WP, Nabel GJ. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005; 79: 8024-8031.
58. Xu J, Ren L, Huang X, Qiu C, Liu Y, Liu Y, et al. Sequential priming and boosting with hetorologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS 2006; 20: 2293-2303.
59. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 2006; 28: 255-265.
60. Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, et al. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front Biosci 2008; 13: 609-620.
61. DeVico AL. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. Curr HIV Res 2007; 5: 561-571.
62. Zhang PF, Chain F, Dong M, Choudhary A, Bouma P, Zhang Z, et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 2007; 104: 10193-10198.